Johnson & Johnson (JNJ) Stock Price Prediction
AI-generated price target with bull & bear cases · Re-evaluated every trading morning and evening
Our AI model’s current price target for JNJ is $264.62 — 2.0% above the latest price of $259.33.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The bull case for JNJ is underpinned by its leading position in the healthcare industry and a diversified portfolio. The company's strategic restructuring and intensified focus on high-growth areas like oncology and MedTech are expected to drive potential double-digit growth. Significant pipeline advancements, particularly in oncology with drugs like Tecvayli, and new product launches are anticipated to be major growth catalysts. JNJ's consistent revenue generation, robust cash flows, disciplined capital allocation, and ongoing commitment to shareholder returns through dividends and share buybacks make it a resilient investment, especially in a defensive sector.
Bear Case
The bear case for JNJ highlights several potential headwinds. These include a possible slowdown in its Pharmaceutical division's growth due to increased competition from biosimilars, such as the loss of exclusivity for Stelara. Commercialization challenges for its substantial investments in robotic-assisted surgery and competition from specialized smaller firms could also impact performance. Furthermore, ongoing litigation related to talc and opioids, coupled with potential market share losses in its electrophysiology business, pose significant financial risks. The company also faces persistent regulatory and pricing pressures across global markets. Some intrinsic valuation models suggest that the stock may currently be overvalued.
Model-assessed risk level: Low
Key Catalysts to Watch
Upcoming quarterly earnings reports, with Q2 2026 results expected on July 15.
Successful product launches and approvals in its Innovative Medicine and MedTech segments, including advancements in oncology and robotic surgery systems.
Strategic partnerships and mergers and acquisitions (M&A) activities, such as the Firefly Bio acquisition.
Continued rotation of investor capital into defensive healthcare stocks amid broader market uncertainty.
Positive clinical trial results and favorable regulatory updates for new drug candidates.
Technical Backdrop
RSI-14
73.2
50-Day MA
$240.94
200-Day MA
$199.60
From 52-Wk High
0.0%
Full momentum breakdown: Is JNJ overbought or oversold?
Model Notes
Johnson & Johnson (JNJ) is a global healthcare conglomerate focused on its Innovative Medicine (pharmaceuticals, especially oncology and immunology) and MedTech (medical devices) segments. The company recently divested its consumer health division, Kenvue, to streamline operations and concentrate on higher-margin businesses. JNJ is recognized for its strong financial foundation, consistent revenue growth, and commitment to shareholder returns, including a long history of increasing dividends, earning it the status of a 'Dividend King'.
JNJ is currently exhibiting a strong bullish trend, trading within a rising channel in the medium to long term. The stock has broken through a significant resistance level, signaling further potential upside. Its price is comfortably above key moving averages (5, 20, 50, 100, and 200-day Simple and Exponential Moving Averages), which typically indicates strong buying pressure. The Relative Strength Index (RSI) is in the 73-74 range, suggesting the stock is overbought but also reflecting robust buying conviction. The Moving Averages Convergence Divergence (MACD) indicator shows a 'golden cross' with accelerating upward momentum.
Current Street Context
July 6, 2026The AI price target for Johnson & Johnson is $264.62. The company's next earnings report is anticipated on July 15, 2026. For the second quarter of 2026, analysts are forecasting an EPS of $2.83, which would represent a 2.17% increase year-over-year. Management has also provided an updated 2026 operational sales guidance of 5.9%–6.9% and adjusted EPS guidance of $11.30–$11.50. The AI price target is slightly above the current market price, aligning with the generally positive sentiment from analysts regarding the company's growth prospects and pipeline.
Frequently Asked Questions
What is the price target for JNJ?
How is this forecast generated?
How accurate are stock price predictions?
Will JNJ stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews JNJ’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on JNJ
Johnson & Johnson Overview
Price, chart, analysis & financials
JNJ: Overbought or Oversold?
Updated daily
JNJ: Why Is It Moving?
Updated daily
JNJ: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers